FENNEC PHARMACEUTICALS INC.
Close on Oct 19, 2026
- Market cap
- $374.14M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 24, 2026 | After market close | – | $-0.17 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 7, 2023 | After market close | $6.52M | $-0.07 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 4, 2023 | During market hours | $3.33M | $-0.21 | – |
| Q4 FY2019 Ended Dec 31, 2019 | Feb 14, 2020 | During market hours | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Nov 12, 2019 | During market hours | – | – | – |
| Q2 FY2019 Ended Jun 30, 2019 | Aug 9, 2019 | During market hours | – | – | – |
| Q1 FY2019 Ended Mar 31, 2019 | May 9, 2019 | After market close | – | – | – |
| Q4 FY2018 Ended Dec 31, 2018 | Mar 14, 2019 | Before market open | – | – | – |
| Q2 FY2010 Ended Jun 30, 2010 | Aug 16, 2010 | During market hours | – | – | – |
| Q4 FY2006 Ended Dec 31, 2006 | Mar 28, 2007 | During market hours | – | – | – |
Press releases
Announcements Fennec Pharmaceuticals filed with the SEC
FENNEC PHARMACEUTICALS ANNOUNCES NEW RESEARCH supporting INTEGRATION AND use of pedmark ® at the 2026 ASCO Annual Meeting
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES ACCEPTANCE of ABSTRACTS at the 2026 ASCO Annual Meeting
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED STUDY to be Conducted by University of Arizona Cancer Center
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS REPORTS FOURTH Quarter AND FULL YEAR 2025 FINANCIAL RESULTS and provides business update
Results of operations · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES CLINICAL RESEARCH COLLABORATION WITH TAMPA GENERAL HOSPITAL CANCER INSTITUTE
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED TRIAL to be Conducted by CITY OF HOPE IN Metastatic Testicular Germ Cell Tumors
Other events · EX-99.1 to Form 8-K
PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM INVESTIGATOR-INITIATED CLINICAL STUDY OF PEDMARK ® IN JAPAN TO
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES FULL DEBT REDEMPTION
Material agreement · Other events · EX-99.1 to Form 8-K
PRIVATE OFFERING OF COMMON SHARES IN CANADA
Material agreement · Other events · EX-99.1 to Form 8-K
PRIVATE OFFERING OF COMMON SHARES IN CANADA
Material agreement · Other events · EX-99.2 to Form 8-K
ANNOUNCES PROPOSED OFFERING OF COMMON SHARES
Material agreement · Other events · EX-99.1 to Form 8-K
ANNOUNCES PRICING OF OFFERING OF COMMON SHARES
Material agreement · Other events · EX-99.2 to Form 8-K
FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF PEDMARQSI Ò IN GERMANY
Other events · EX-99.1 to Form 8-K
PHARMACEUTICALS ANNOUNCES PEDMARQSI Ò POSITIVE
Other events · EX-99.1 to Form 8-K
ANNOUNCES EARLY PARTIAL REPAYMENT OF ITS OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT
Material agreement · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth
Executive or director change · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Other events · EX-99.1 to Form 8-K
Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND
Results of operations · EX-99.1 to Form 8-K
Fennec Pharmaceuticals and Norgine Enter into
Material agreement · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
Results of operations · EX-99.1 to Form 8-K/A
Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
Other events · EX-99.1 to Form 8-K
Issues Reminder of Non-Substitution of PEDMARK Ò
Other events · EX-99.1 to Form 8-K
INCREMENTAL $5 MILLION INVESTMENT FROM PETRICHOR
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER
Results of operations · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces PEDMARK ® (sodium thiosulfate injection) Receives
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Availability of PEDMARK ® (sodium thiosulfate injection) in the
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS ANNOUNCES SECOND CLOSING OF $20 MILLION INVESTMENT
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces FDA Approval of PEDMARK®
Other events · EX-99.1 to Form 8-K
FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K